This inventor holds 3 USPTO granted patents. Top assignee: Other. Active years: 1999.
Location History:
- Grankulla, FI (1999)
- SF-02700 Grankulla, FI (1999)
Company Filing History:
3 out of 834,350 Years Active: 1999
Title: Ulf-Hangkan Stenman: Innovator in Prostate Cancer Diagnostics
Introduction
Ulf-Hangkan Stenman is a notable inventor based in Grankulla, Finland. He has made significant contributions to the field of medical diagnostics, particularly in the area of prostate cancer. With a total of 3 patents to his name, Stenman has developed innovative methods that enhance the accuracy of prostate cancer diagnosis.
Latest Patents
Stenman's latest patents include the "Assay of free and complexed trypsinogen-2" and the "Assay of free and complexed prostate-specific antigen (PSA)." These inventions utilize immunoassays to measure both free PSA and proteinase inhibitor complexes. The method employs at least two different monoclonal antibodies in a non-competitive immunoassay format. Furthermore, the PSA proteinase inhibitor complex of interest is formed with .alpha..sub.1-antichymotrypsin, .alpha..sub.1-protease inhibitor (API), or .alpha..sub.2-macroglobulin. The invention is particularly valuable as it applies the measurements of free PSA, the PSA-proteinase inhibitor complex, and their ratio in diagnosing patients with prostate cancer.
Career Highlights
Throughout his career, Ulf-Hangkan Stenman has focused on advancing diagnostic techniques that improve patient outcomes. His work has been instrumental in the development of assays that provide critical information for the early detection of prostate cancer. Stenman's innovative approaches have garnered attention in the medical community, establishing him as a key figure in this field.
Collaborations
Stenman has collaborated with notable professionals such as Hans Lilja and Johan Hedstrom. These partnerships have further enriched his research and contributed to the success of his inventions.
Conclusion
Ulf-Hangkan Stenman is a distinguished inventor whose work in prostate cancer diagnostics has made a significant impact. His innovative patents and collaborations highlight his commitment to improving medical diagnostics. His contributions continue to influence the field and enhance patient care.